Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Moderna (MRNA – Research Report) and Inhibikase Therapeutics (IKT – Research Report).
Moderna (MRNA)
Brookline Capital Markets analyst Leah R. Cann maintained a Buy rating on Moderna today and set a price target of $506.00. The company’s shares closed last Thursday at $182.18.
According to TipRanks.com, Cann ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Moderna with a $200.38 average price target, which is an 11.9% upside from current levels. In a report issued on November 28, Barclays also maintained a Buy rating on the stock with a $210.00 price target.
See the top stocks recommended by analysts >>
Inhibikase Therapeutics (IKT)
JonesTrading analyst Soumit Roy maintained a Hold rating on Inhibikase Therapeutics today. The company’s shares closed last Thursday at $0.49, close to its 52-week low of $0.44.
According to TipRanks.com, Roy is a 4-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Inhibikase Therapeutics.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MRNA:
- Pfizer dismisses Moderna claim it copied COVID-19 shot, CNBC reports
- Moderna call volume above normal and directionally bullish
- MRNA, BIIB, or IQV: Which Biotech Stock Earns the Street’s “Strong Buy” Rating?
- Early notable gainers among liquid option names on November 28th
- Barclays reiterates $210 target on Moderna after PSV deep dive
